Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections. 2020

Vasilios Petrakis, and Periklis Panagopoulos, and Nikolaos Papanas
University Hospital of Alexandroupolis, Alexandroupolis, Greece.

New antimicrobial agents have been developed to treat infections caused by methicillin-resistant Staphylococcus aureus and other multidrug-resistant pathogens. Dalbavancin is a novel semisynthetic lipoglycopeptide antibiotic, particularly active against methicillin-resistant Staphylococcus aureus. Due to its unique pharmacological characteristics and longer half-life, it can be administered once-weekly or every 15 days and in outpatient setting. Currently, it is indicated for complicated skin and soft tissue infections, but accumulating evidence points to its off-label efficacy in osteomyelitis and endocarditis. Further experience is still needed to increase our knowledge on the role of dalbavancin in a wider range of Gram-positive infections requiring prolonged antimicrobial treatment.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D012874 Skin Diseases, Infectious Skin diseases caused by bacteria, fungi, parasites, or viruses. Infectious Skin Diseases,Disease, Infectious Skin,Diseases, Infectious Skin,Infectious Skin Disease,Skin Disease, Infectious
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D016908 Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method. Bacterial Infections, Gram-Positive,Infections, Gram-Positive Bacterial,Bacterial Infection, Gram-Positive,Bacterial Infections, Gram Positive,Gram Positive Bacterial Infections,Gram-Positive Bacterial Infection,Infection, Gram-Positive Bacterial,Infections, Gram Positive Bacterial
D017334 Teicoplanin Lipoglycopeptide antibiotic from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety. Teichomycin,Targocid,Teichomycin A2
D018461 Soft Tissue Infections Infections of non-skeletal tissue, i.e., exclusive of bone, ligaments, cartilage, and fibrous tissue. The concept is usually referred to as skin and soft tissue infections and usually subcutaneous and muscle tissue are involved. The predisposing factors in anaerobic infections are trauma, ischemia, and surgery. The organisms often derive from the fecal or oral flora, particularly in wounds associated with intestinal surgery, decubitus ulcer, and human bites. (From Cecil Textbook of Medicine, 19th ed, p1688) Infections, Soft Tissue,Infection, Soft Tissue,Soft Tissue Infection

Related Publications

Vasilios Petrakis, and Periklis Panagopoulos, and Nikolaos Papanas
February 2008, Therapeutics and clinical risk management,
Vasilios Petrakis, and Periklis Panagopoulos, and Nikolaos Papanas
December 2019, Diagnostic microbiology and infectious disease,
Vasilios Petrakis, and Periklis Panagopoulos, and Nikolaos Papanas
June 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Vasilios Petrakis, and Periklis Panagopoulos, and Nikolaos Papanas
August 2008, Infection,
Vasilios Petrakis, and Periklis Panagopoulos, and Nikolaos Papanas
October 2009, Surgical infections,
Vasilios Petrakis, and Periklis Panagopoulos, and Nikolaos Papanas
April 2018, Current opinion in infectious diseases,
Vasilios Petrakis, and Periklis Panagopoulos, and Nikolaos Papanas
March 2006, The Annals of pharmacotherapy,
Vasilios Petrakis, and Periklis Panagopoulos, and Nikolaos Papanas
November 2003, American journal of surgery,
Vasilios Petrakis, and Periklis Panagopoulos, and Nikolaos Papanas
February 2008, Expert review of anti-infective therapy,
Vasilios Petrakis, and Periklis Panagopoulos, and Nikolaos Papanas
October 2007, Zentralblatt fur Chirurgie,
Copied contents to your clipboard!